Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PROCRIT Clear all
Completed Phase 2 Interventional Results available

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01381094
View directory record Official record
Conditions
Anemia, Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Pine Bluff, Arkansas • Covina, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 3 Interventional

A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

NCT00081471
View directory record Official record
Conditions
Anemia
Interventions
darbepoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
22
States / cities
Los Angeles, California • Mather, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

NCT04269707
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric carboxymaltose
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Miami, Florida • Miami Springs, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01628107
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
108
States / cities
Azusa, California • Bellflower, California • Commerce, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma

NCT00400686
View directory record Official record
Conditions
Anemia, Multiple Myeloma, Plasma Cell Neoplasm
Interventions
epoetin alfa
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 29, 2026, 5:28 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Acute Erythropoietin on Hepcidin and Dietary Iron Absorption Following Military-relevant Exercise in Energy Deficit: Pilot Study

NCT07517562
View directory record Official record
Conditions
Iron Absorption
Interventions
Exercise test
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 29, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Erythropoietin in Myelodysplastic Syndrome

NCT00723112
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Oct 29, 2026, 5:28 AM EDT
Terminated Phase 4 Interventional Results available

Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin

NCT03277183
View directory record Official record
Conditions
Anemia, CKD, Atherosclerosis, Cardiovascular
Interventions
Low dose erythropoietin, High dose erythropoietin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Colorado-Oregon Altitude Study

NCT05734716
View directory record Official record
Conditions
Acute Mountain Sickness
Interventions
Erythropoietin, Iron sucrose (Venofer), Sterile Sodium Chloride
Drug
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Leadville, Colorado • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia

NCT00006136
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
arginine butyrate, epoetin alfa
Drug
Lead sponsor
Boston University
Other
Eligibility
3 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Oakland, California • New Haven, Connecticut • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2005 · Synced Oct 29, 2026, 5:28 AM EDT
Active, not recruiting Phase 3 Interventional

Vafseo Outcomes In-Center Experience

NCT06520826
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
Vadadustat, Erythropoiesis Stimulating Agent
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Lone Tree, Colorado • Dalton, Georgia • Gallup, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

NCT00255749
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

NCT01628120
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
115
States / cities
Azusa, California • Bakersfield, California • Bellflower, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 29, 2026, 5:28 AM EDT
Recruiting Phase 1 Interventional

Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage

NCT05617833
View directory record Official record
Conditions
Intraventricular Hemorrhage of Prematurity
Interventions
MLT+EPO, Placebo
Combination Product · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Hours to 2 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
St. Petersburg, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01235936
View directory record Official record
Conditions
Anemia, Kidney Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Augusta, Georgia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

NCT02260193
View directory record Official record
Conditions
Anemia, End Stage Renal Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
El Granada, California • Long Beach, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

NCT00513240
View directory record Official record
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
Interventions
Erythropoetin, Normal saline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Day to 30 Days
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

NCT01975818
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY 85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Azusa, California • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 29, 2026, 5:28 AM EDT
Withdrawn Phase 2 Interventional

Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia

NCT00481624
View directory record Official record
Conditions
Anemia
Interventions
Epoetin Alfa plus Iron
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants

NCT01235923
View directory record Official record
Conditions
Preterm Infants
Interventions
three times weekly Epo, weekly Epo
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
7 Days to 100 Days
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 29, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

NCT00910858
View directory record Official record
Conditions
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Interventions
Lenalidomide, Recombinant human erythropoietin
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 29, 2026, 5:28 AM EDT
Terminated Phase 4 Interventional Results available

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa

NCT00626574
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Epoetin alfa, Saline
Drug
Lead sponsor
University of South Florida
Other
Eligibility
30 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 29, 2026, 5:28 AM EDT
Completed No phase listed Observational

Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery

NCT01393418
View directory record Official record
Conditions
Erythropoietin, Acute Kidney Injury, Renal Biomarker
Interventions
Cardiac Surgery
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 29, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

NCT00589953
View directory record Official record
Conditions
Infant, Premature, Erythropoietin, Brain Injury, Intraventricular Hemorrhage, Periventricular Leukomalacia, Neurodevelopmental Outcomes, Randomized Clinical Trial
Interventions
Erythropoietin, Saline placebo
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
Up to 24 Hours
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 29, 2026, 5:28 AM EDT